0001140361-24-025173.txt : 20240509 0001140361-24-025173.hdr.sgml : 20240509 20240509160650 ACCESSION NUMBER: 0001140361-24-025173 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC. CENTRAL INDEX KEY: 0001368514 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 562590442 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36728 FILM NUMBER: 24930511 BUSINESS ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 BUSINESS PHONE: (201) 478-5552 MAIL ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 FORMER COMPANY: FORMER CONFORMED NAME: R&R ACQUISITION VI, INC DATE OF NAME CHANGE: 20060707 8-K 1 ef20028782_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 9, 2024

ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)
          
Delaware
001-36728
56-2590442
(State or other jurisdiction of incorporation)
 (Commission File Number)  (IRS Employer Identification No.)
          
465 State Route 17, Ramsey, New Jersey
  
07446
(Address of principal executive offices)
  
(Zip Code)

Registrant’s telephone number, including area code: (201) 478-5552

 
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
ADMA
Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02
Results of Operations and Financial Condition

On May 9, 2024, ADMA Biologics, Inc. issued a press release announcing its financial results for the three months ended March 31, 2024, and provided a business update. A copy of the press release is furnished herewith as Exhibit 99.1.*

Item 9.01
Exhibits.

(d) Exhibits

Exhibit No.
Description
ADMA Biologics, Inc. Press Release, dated May 9, 2024
104
Cover Page Interactive Data File (embedded with the Inline XBRL document)

* The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

2
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

May 9, 2024
ADMA Biologics, Inc.
   
 
By:
/s/ Adam S. Grossman
   
Name:
Adam S. Grossman
   
Title:
President, Chief Executive Officer and Interim Chief Financial Officer


3
 EX-99.1 2 ef20028782_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

 
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
 
1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y
 
1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y
 
1Q 2024 Adjusted EBITDA(1) of $26.4 Million, a 970% Increase Y-o-Y
 
FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million and $410 Million, Respectively
 
FY 2024 Net Income Guidance Increased to More Than $85 Million and Adjusted EBITDA Guidance Increased to More Than $110 Million
 
FY 2025 Net Income Guidance Increased to More than $135 Million and Adjusted EBITDA Guidance Increased to More Than $160 Million
 
Conference Call Scheduled for Today at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, FL, May 9, 2024 - ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its first quarter 2024 financial results and provided a business update.
 
“ADMA’s commercial success continues to unfold, and during the first quarter of 2024, we surpassed our financial expectations and delivered compounding earnings growth. The versatility and strength of our innovative business model has yet again provided for significant increases to both top- and bottom-line projections for 2024 and 2025,” said Adam Grossman, President, Chief Executive Officer and Interim Chief Financial Officer of ADMA. “We believe ASCENIV™’s record utilization coupled with BIVIGAM®’s deepening entrenchment in the expanding U.S. IG market are driving our commercial growth and further solidifying our position as a leader in specialty biologics. With an unwavering commitment to serving immune deficient patients, we believe we are poised for enduring growth within our target markets for years to come.”
 
Mr. Grossman continued, “Looking to the remainder of 2024, we are actively advancing our growth initiatives, including innovating our biologics production processes and enhancing yields, as well as progressing our preclinical pipeline program. We anticipate strong performance throughout the year and remain confident in our ability to exceed expectations and deliver value to our stakeholders, as well as further de-risking long-term growth initiatives.”
 
First Quarter 2024 Milestones and Objectives:
 
(1) Adjusted EBITDA is a non-GAAP financial measure. For a reconciliation of Adjusted EBITDA to the most comparable GAAP measure, please see the reconciliation included in the financial tables.


 •
Compounding Growth. Driven by 44% year-over-year revenue growth and an expansion of gross margins to 48%, ADMA grew Adjusted EBITDA and Net Income to $26.4 million and $17.8 million, respectively, during the first quarter. The Company anticipates building on this momentum throughout the remainder of 2024 and beyond.
 

 •
Strengthened Balance Sheet.  Based on ADMA’s first quarter Adjusted EBITDA growth, the Company’s current net leverage ratio has organically improved to 0.85x. The Company anticipates continued strengthening of the balance sheet driven by forecasted Adjusted EBITDA growth and by what we believe will be a significant increase in free cash flow beginning in the second quarter of 2024 and beyond.
 

 •
ADMAlytics™. During the first quarter of 2024, a white paper was published showcasing the potential utility of ADMAlytics, an innovative AI platform. Key points covered leveraging data lakes, advanced analytics, and generative AI for plasma pool efficiency, donor and inventory management, yield predictions, and KPI monitoring. All told, we anticipate ADMAlytics’ ongoing rollout across the organization will provide for operational and financial benefits, including the following: increased production efficiency, added visibility into the 7–12-month manufacturing process, optimized future commercial planning, streamlined plasma pooling, and reduced variability and FTE hours. Collectively, we expect these efficiencies will further solidify the Company’s rapid earnings growth outlook.
 
Upwardly Revised 2024-2025 Financial Guidance:
 

 •
FY 2024 and 2025 total revenue is now expected to be more than $355 million and $410 million, respectively, increased from prior guidance of more than $330 million and $380 million, respectively.
 

 •
FY 2024 and 2025 net income is now expected to exceed $85 million and $135 million, respectively, increased from prior guidance of $65 million and $115 million, respectively.
 

 •
FY 2024 Adjusted EBITDA is now anticipated to exceed $110 million, increased from over $90 million previously; FY 2025 Adjusted EBITDA expected to exceed $160 million, increased from over $140 million previously.
 
Advancing Innovative Growth Opportunities: Below are the Company’s ongoing initiatives which, if successful, we believe represent potential upside to newly provided guidance ranges:
 

 •
Biologic Production Yield Enhancement: The Company continues to progress with development scale and laboratory analyses, advancing the Company’s initiative to capture additional immune globulin (IG) production yields with the same quantities of starting raw material. These initiatives are subject to further evaluation, validation of commercial-scale production and requisite regulatory review. If proven successful, we believe these yield enhancements will potentially provide significant upside to the Company’s peak financial targets in the future.
 

 •
New Pipeline Introduction - S. pneumonia Hyperimmune Globulin:
 
o          S. pneumonia is the leading cause of community-acquired pneumonia in the U.S., ranking ninth in overall mortality. Rising anti-infective resistance emphasizes the need for interventions. Each year, around one million U.S. adults develop pneumococcal pneumonia, resulting in 400,000 hospitalizations and 5-7% mortality, with approximately 7,000 deaths due to resistance. Despite available vaccines, vaccine-naive and immune-compromised individuals remain at risk. A hyperimmune globulin could offer immediate neutralizing antibodies, benefiting both in-patient and out-patient settings. If approved, we estimate the S. pneumonia hyperimmune globulin product could generate annual revenue of $300-500 million.

o          ADMA holds various U.S. and foreign patents, including U.S. Patent Nos. 10,259,865 and 11,084,870, and EP Patent No. 3375789, each with patent terms extending to 2037, along with numerous pending applications. These patents cover ADMA’s proprietary pneumococcal hyperimmune technology, encompassing hyperimmune anti-pneumococcal immune globulin, methods of preparation, and utilization for treating S. pneumonia infections or providing immunotherapy to patients. During 2024, ADMA intends to advance pre-clinical work for the S. pneumonia program.


 •
ASCENIV Label Expansion: The ongoing post-marketing pediatric clinical study for ASCENIV may provide label expansion opportunities, further strengthening ADMA’s product portfolio, if successful.
 
First Quarter 2024 Financial Results:

Total revenues were $81.9 million for the quarter ended March 31, 2024, as compared to $56.9 million for the quarter ended March 31, 2023, an increase of $25.0 million, or approximately 44%. The increase is primarily related to increased sales of our immunoglobulin products.

Gross profits were $39.1 million for the quarter ended March 31, 2024, as compared to $16.5 million for the quarter ended March 31, 2023, an increase of $22.6 million. As a result, ADMA achieved a corporate gross margin of 48% in the first quarter of 2024 as compared to 29% in the first quarter of 2023.

Adjusted EBITDA was $26.4 million for the quarter ended March 31, 2024, as compared to Adjusted EBITDA of $2.5 million for the quarter ended March 31, 2023, an increase of $24.0 million, or approximately 970%.

GAAP Net income was $17.8 million for the quarter ended March 31, 2024, compared to a GAAP Net Loss of $6.8 million for the quarter ended March 31, 2023.

As of March 31, 2024, ADMA had working capital of approximately $223.3 million, primarily consisting of $177.7 million of inventory, $45.3 million of cash and cash equivalents and $49.6 million of net accounts receivable, partially offset by current liabilities of $53.1 million.
 
Conference Call Information

To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call).
 
Attendees who do not intend to ask a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.
 
About ASCENIV™
 
ASCENIV (immune globulin intravenous, human – slra 10% liquid) is a plasma-derived, polyclonal, intravenous immune globulin (IVIG). ASCENIV was approved by the United States Food and Drug Administration (FDA) in April 2019 and is indicated for the treatment of primary humoral immunodeficiency (PI), also known as primary immune deficiency disease (PIDD), in adults and adolescents (12 to 17 years of age). ASCENIV is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and respiratory syncytial virus (RSV) plasma obtained from donors tested using the Company’s proprietary microneutralization assay. ASCENIV contains naturally occurring polyclonal antibodies, which are proteins that are used by the body’s immune system to neutralize microbes such as bacteria and viruses that safeguard against infection and disease. ASCENIV is protected by numerous issued patents in the United States and internationally and a wide range of patent applications worldwide. Certain data and other information about ASCENIV can be found by visiting www.asceniv.com. Information about ADMA and its products can be found on the Company’s website at www.admabiologics.com.
 
Additional Important Safety Information About ASCENIV™
 
WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE

Thrombosis may occur with immune globulin intravenous (IGIV) products, including ASCENIV. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
 
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients.
 
Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. ASCENIV does not contain sucrose.
 
For patients at risk of thrombosis, renal dysfunction or renal failure, administer ASCENIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

ASCENIV™ Contraindications:
 
History of anaphylactic or severe systemic reactions to human immunoglobulin.
 
IgA deficient patients with antibodies to IgA and a history of hypersensitivity.
 
ASCENIV™ Warnings and Precautions:
 
IgA-deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions. Have medications such as epinephrine available to treat any acute severe hypersensitivity reactions. [4, 5.1]
 
Thrombotic events have occurred in patients receiving IGIV treatments. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for patients at risk of hyperviscosity. [5.2, 5.4]
 
In patients at risk of developing acute renal failure. monitor renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output. [5.3, 5.9]
 
Hyperproteinemia, increased serum viscosity, and hyponatremia or pseudohyponatremia can occur in patients receiving IGIV treatment.
 
Aseptic meningitis syndrome (AMS) has been reported with IGIV treatments, especially with high doses or rapid infusion. [5.5]
 
Hemolytic anemia can develop subsequent to IGIV treatment. Monitor patients for hemolysis and hemolytic anemia. [5.6]
 
Monitor patients for pulmonary adverse reactions (Transfusion-related acute lung injury [TRALI]). If transfusion related acute lung injury is suspected, test the product and patient for antineutrophil antibodies. [5.7]
 
Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
 
ASCENIV™ Adverse Reactions:
 
The most common adverse reactions to ASCENIV (≥5% of study subjects) were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea
 
To report SUSPECTED ADVERSE REACTIONS, contact ADMA Biologics at (800) 458-4244 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
 
About ADMA Biologics, Inc. (ADMA)
 
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty biologics and human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.
 
Use of Non-GAAP Financial Measures
 
This press release includes certain non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The Company believes Adjusted EBITDA is useful to investors in evaluating the Company’s financial performance. The Company uses Adjusted EBITDA as a key performance measure because we believe that it facilitates operating performance comparisons from period to period that exclude potential differences driven by the impact of variations of non-cash items such as depreciation and amortization, as well as stock-based compensation or certain non-recurring items. The Company believes that investors should have access to the same set of tools used by our management and board of directors to assess our operating performance. Adjusted EBITDA should not be considered as a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing the Company’s financial performance. Accordingly, this key business metric has limitations as an analytical tool. It should not be considered as an alternative to net income/loss or any other performance measures derived in accordance with GAAP and may be different from similarly titled non-GAAP measures used by other companies. Please refer to the tables below for the reconciliation of GAAP measures to non-GAAP measures for applicable periods.
 
Cautionary Note Regarding Forward-Looking Statements
 
This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “confident,” “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about the Company’s future results of operations, including, but not limited to, revenue, net income and Adjusted EBITDA guidance in future periods, and certain assumptions in connection therewith; the market for ASCENIV and BIVIGAM; the potential utility of ADMAlytics; and additional growth opportunities, including but not limited to, the Company’s yield enhancement initiative and production processes, the newly announced hIG pipeline program targeting S. pneumonia (including the revenue potential) and ASCENIV label expansion. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.
 
INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com

ADMA BIOLOGICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

    
March 31,
2024
    
December 31,
2023
  
   
(Unaudited)
        
   
(In thousands, except share data)
  
ASSETS
            
Current assets:
            
Cash and cash equivalents
  
$
45,325
    
$
51,352
  
Accounts receivable, net
    
49,621
      
27,421
  
Inventories
    
177,732
      
172,906
  
Prepaid expenses and other current assets
    
3,741
      
5,334
  
Total current assets
    
276,419
      
257,013
  
Property and equipment, net
    
55,317
      
53,835
  
Intangible assets, net
    
321
      
499
  
Goodwill
    
3,530
      
3,530
  
Right-to-use assets
    
9,397
      
9,635
  
Deposits and other assets
    
5,891
      
4,670
  
TOTAL ASSETS
  
$
350,875
    
$
329,182
  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY
                
Current liabilities:
                
Accounts payable
  
$
17,186
    
$
15,660
  
Accrued expenses and other current liabilities
    
33,691
      
32,919
  
Current portion of deferred revenue
    
1,118
      
182
  
Current portion of lease obligations
    
1,093
      
1,045
  
Total current liabilities
    
53,088
      
49,806
  
Senior notes payable, net of discount
    
130,847
      
130,594
  
Deferred revenue, net of current portion
    
1,654
      
1,690
  
End of term fee
    
1,688
      
1,688
  
Lease obligations, net of current portion
    
9,487
      
9,779
  
Other non-current liabilities
    
405
      
419
  
TOTAL LIABILITIES
    
197,169
      
193,976
  
                 
COMMITMENTS AND CONTINGENCIES
                
                 
STOCKHOLDERS' EQUITY
                
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding
    
-
      
-
  
Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 231,769,765 and 226,063,032 shares issued and outstanding
    
23
      
23
  
Additional paid-in capital
    
642,133
      
641,439
  
Accumulated deficit
    
(488,450
)
    
(506,256
)
TOTAL STOCKHOLDERS' EQUITY
    
153,706
      
135,206
  
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
  
$
350,875
    
$
329,182
  

ADMA BIOLOGICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

   
Three Months ended March 31,
  
   
2024
    
2023
  
   
(Unaudited)
        
   
(In thousands, except share and per share data)
  
             
REVENUES
  
$
81,875
    
$
56,914
  
Cost of product revenue
    
42,767
      
40,401
  
Gross profit
    
39,108
      
16,513
  
                 
OPERATING EXPENSES:
                
Research and development
    
450
      
855
  
Plasma center operating expenses
    
1,005
      
1,780
  
Amortization of intangible assets
    
193
      
179
  
Selling, general and administrative
    
15,639
      
14,512
  
Total operating expenses
    
17,287
      
17,326
  
                 
INCOME (LOSS) FROM OPERATIONS
    
21,821
      
(813
)
                 
OTHER INCOME (EXPENSE):
                
Interest income
    
384
      
166
  
Interest expense
    
(3,769
)
    
(6,115
)
Other expense
    
(35
)
    
(27
)
Other expense, net
    
(3,420
)
    
(5,976
)
                 
INCOME (LOSS) BEFORE INCOME TAXES
    
18,401
      
(6,789
)
                 
Provision for income taxes
    
595
      
-
  
                 
NET INCOME (LOSS)
  
$
17,806
    
$
(6,789
)
                 
BASIC EARNINGS (LOSS) PER COMMON SHARE
  
$
0.08
    
$
(0.03
)
DILUTED EARNINGS (LOSS) PER COMMON SHARE
  
$
0.08
    
$
(0.03
)
                 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
                
Basic
    
228,874,847
      
221,921,750
  
Diluted
    
236,414,374
      
221,921,750
  

NON-GAAP RECONCILIATION
RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA

   
Three Months Ended March 31,
  
   
2024
    
2023
  
   
(in thousands)
  
Net income (loss)
  
$
17,806
    
$
(6,789
)
Depreciation
    
1,921
      
1,854
  
Amortization
    
193
      
179
  
Income taxes
    
595
      
-
  
Interest expense
    
3,769
      
6,115
  
EBITDA
    
24,284
      
1,359
  
Stock-based compensation
    
2,141
      
1,110
  
Adjusted EBITDA
  
$
26,425
    
$
2,469
  


EX-101.SCH 3 adma-20240509.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 adma-20240509_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 adma-20240509_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image0.jpg begin 644 image0.jpg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htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
May 09, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 09, 2024
Entity File Number 001-36728
Entity Registrant Name ADMA BIOLOGICS, INC.
Entity Central Index Key 0001368514
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 56-2590442
Entity Address, Address Line One 465 State Route 17
Entity Address, City or Town Ramsey
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07446
City Area Code 201
Local Phone Number 478-5552
Title of 12(b) Security Common Stock
Trading Symbol ADMA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://admabiologics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports adma-20240509.xsd adma-20240509_lab.xml adma-20240509_pre.xml ef20028782_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20028782_8k.htm": { "nsprefix": "adma", "nsuri": "http://admabiologics.com/20240509", "dts": { "schema": { "local": [ "adma-20240509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "adma-20240509_lab.xml" ] }, "presentationLink": { "local": [ "adma-20240509_pre.xml" ] }, "inline": { "local": [ "ef20028782_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://admabiologics.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240509to20240509", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20028782_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240509to20240509", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20028782_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001140361-24-025173-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-025173-xbrl.zip M4$L#!!0 ( -B J5CG^K*@1P, $@/ 1 861M82TR,#(T,#4P.2YX M&E.,Y(3K M>R'S6S)%"Z;'P>\%8G1*218 LPJN1BM51!5 9]:D;H=IXB.)R)E\@$[ K3.E%+J-<%48=]F'!DPQ;3@W$*T\0C M38EL Z=(31S(1[:$E-3'\NM0"3 E X M&L2YT$B;^G13U6114#X5U8R9LSLZ M\J?P3*; [?'($HX#1?."V0UTB?+8NA2=ME&0AA_W<]EN>;60&P M@^_/#R?:T%FZ%7AAF_\]S^ZXIGK]8(Y>YF[G T"S<7 RHU;W^AF94DY=1<7F M;HAC (%G: X1ST!)!QI\5]$NR2[_0I'LB5^[\6Z55.@JY102(X87[ +@QMEQ M7#7K3\)W5K336N7$=@/:]C.%)Z0&?.\*;W;_#*&B:O[RXG\4V-&4VCMQT)SWLIMM!!U4L%ES+=1OE)L1_='&PD-+\D+>S MT,347QU,D!6>MS%0Y[M1!V&.S 721GD#*(<=M!7%;91]NAVT4]V]P(?E;6#2@\G;[CYT:P_Z$OWM[=2%;+7]/M^-NAU \ZUVSL(= MQ'Y!C[/+3^WRT^1B%_U(VE_M,PVX;"O;A_$[F,3M=GWOW7FFJ@=8X<'9DL>> MEAU^71Q-U[:KGD;&']:0K J&.-)"KN_-]_DMT&2YVY!OQ'/SC M)IB-"%^/@[=O) M^(]/%[?1 UZ&PR3+BS"+\ Q_6%>-EZ0*"S*,>]T7\]I*AQ,QYM86@4_&@K9 MD#<-)\%P.AFM\WA0#Y&;+8((^;JAK^OD.6=,.Z#OL8T(?%I%OL?N!JJJ\'?%B%]!52:P=PGX'_4P%!3WG3!/DEQ M\;K 68QC$9G[-IP[R]#ER;;TO/%-(LEKRJ\BA#:GDS.OI<<<1Z,%^3*.<<(\ M!U/^8<@_E+-@!_^>$';Y/)[G!0VC0G@J)W$T &U%4O"Q*[:Q/%#>7QHJQ3E9 MT0@K$;0CL$J05-]J6)##9$72 ?BZ$TDWM*EKK<$T/*Z@R4O@Z1)$$%04"_L7>Z M?B71:HFSXHYY5$H/F>HIR"8'M* 8+F0I_G1@2;*9.$+\<+]0@3DG^ES)2.TJ M!%'&4GD ZG>:%.Q4>D*6RU665#?1N5)YHZ:>DD;CP)HQJ@MT.L317BE@D5B84E I4[4KN@=E;DB914K#OI)_830--PE3!1R^HIP<)'%#5 MQW/A%/2J@Q00S[9M2#3N%T]#74A;)F4PFSI!I45I/2!Y33%?!YA-O3Q[\YM3 M>G5_CZF"2[NPGJA)Z(!J>WP79(W>=>@:.LV8;1CM&%%E1:5YOS!;5)+8YER& M6Z\7D+\ #O^PG^?Y"E-KY+5R&'Q WAW^VK%TN B@&)9+H=FUN2 J37_7A;[< M\.IHPP->(XU>FI723I.']7+,(L<\^ED:+A0H05L]5<7F@#T8Q85QU:$.:%DW MVQPB?KQ?3N',$T/"9 (EB<#-7#*/&P)G21Z%Z9\XI&>L1?T&UZ)2M@D:J@YV M##21N]@\:+INVT=0>VRW%"H+XB94VOJQOZ"K&[%*,KSKH(C5#8@V"+RS7.U@ MM],,Z$">)5UG1 /1NV-:=FY']6Z?!M>5L7]D0S4$V=87&Z1[1P[S;8+"(^&; M'Y=^9=]1-72#&H5L1=,!U6#4+HA6';?1+.NW)-<(,P/BEGY0#->*6*06IE>2 MJN2:B^Z!VM.,C?+Y!B\2_D-'5ER&2Q4ADZ2>(BQQ0-84TX58C5\=L*!\5K6B M;3/B[?NEU5@DTIY4F55(*5"UJK4W4D_8(J%A>LZ^Y*U_P\\@JAJ-Q&I#XPRK M)JH[K4W'9EQ5O>"U;D>E 3%+'XC5U8I8I!9B5I'*T+85W1NU9TF*+U?+>6/_ M3&>66-TU.V/:C.5.J.33#.>.5'#)FU#5U@N MSV.&?G)?_Y)G0+%%*W&IU3I#VC(*=V+U D=U66_*"$D#, M:[K("\ 6&F^KX3R+"'TDM Q^6[#[[!.R8M>%YQ,2P[>^5CVDE='2PWE]6(W( M?96TA3&O%7-OL6(DU1M4ZA"AJ-8B+N[#XK&#@+RX2M!",G:4E]/+2/.VJ$Z7 MF"Z2;/&1DJ?BX80L'\,,OCDW*J5%I%$Z+Q[C"-P7C;' O<0B$594F5%M M[\.Z,->36"<>6@=@!YE_.TB\<7\ M^*0\^ K*@Q;*[YY(/RD/;"E7"]Y">=!&>1.,5Z1\:DGYU)+RJ1?*ISXIGWX% MY=,VREF1>GHVG]IRKI:\A?-I&^=--'QS?L(^7M$[\I29*&^J(,9W55T1WHS< M&=^2:RNZ=WHTV.8V_HV56WM$-5 YB&EM@2&BMV*09P,&OFDNO_I>T6M*OB19 M RX;*<1U0]H5W)HQ=$9XT[\5YFJW!NN;[1DAZ1'PNKI"U)L9@-!7>H#\M^'B M_91>;?T8S^>R!#R9"TEG9W(Y9G>G\8U?NW-X+6^>P"M#CU!6JP2>N,%*@F?M M>BL5/&5KBNT;U6N2%V'Z5_*HW74W"2%L%6%7\(+Q.T-8]6X%LMRI@7-E1LS> MF\US8RTAN$U5AQ"7]"#H9CQ\O"R QZ8X! "'3/7D9)/+FP* &$XO"I#]:=\3 ML"N;E;?&_+ ')()))_IDR;3M*C9O"##5R@-1_$5(Z?4#R>#_2Z(SUQ-IFAWH MTL5R(0SPJ:.L(9V5+:ALZL4O[MIB$',"9>I4E2"OM98^GLS&T8HRXB?!_(X/ M4J%"9ZXGU#2[/).MB>7T1';3I_9Y;%4Z*_\@YHR-]7=_N\G),4>.3.H*BG!2H<6#1$=,$1=JLC$E+/ M+@FJ6U'5W(,'\TSU(:T)ESB M],_X-+G\%@DFW))+M#V62'*9MDDG3Z\=(1M@!- M;8N138!_7\E(!,N2;)9DY^:%#]^CJW-UCK\NYO+3)HF]9\PR0M.K5J_3;7DX M#6E$TOE5:Y6U4182TOKT\<_KSOK M?H>RN1]TNSW_KZ^3QW"!$]0F:9:C-,0MC^,OLF+CA(8H+S@?#-],6:P2]/W] M7%:$^-96L+;8U.X%[7ZOL\FBEJ0HP@TF4?!-!2]KZ@T& [^([J$\$7&DWI?- M5\_S=NO':(P?\,P3[W\\C*VC![Y ^"G.)VB*8SYE,3S?+O%5*R/),L9JVX+A MF3E/S-@^C5B=@5B=W@>Q.C^_9/9/H3<79GJB.8I?AV>1K\JU,LWII&]?:VE= ME&]?M3O1;YQQRQ[V"5ZF2G%_#VK(^@ MBJ($30F-Z9R$62>DR2[_9QJN$ISFPY1KEY-\.TYGE"7%R:&>NDC*J05GW?/N MH"#FSG=(=,EPQH%%9,(WE";#FQRG$8[4=(+K2:44$ZNI8QJ69HO%V9"RJBP9 MGZW0),-A9TZ?_0@3KG/0%Q]$X?VB:/[EWQ'EEP'#:98S%.8J4RSTN6H98YRA MJ$F+^6].5"W3$\^H\32%),URJ,SR4,DA*S-&+%29^,>2C-53MD3X2\1XOG:X M(/'> 3-&$]M*4B?U0WH77BF#EU.O/)*R"+.K5E=&^ M^)8"#CG;2#"^B=%<4] 8D^N@Q>!IZ")?(Z(V5*K8 ZRBLMW^O/F9'] M^Z,1 MH^V8&@:>NDV*:;BK:BFDVL$[4/N&9"&*_\:(W? MF45O"TI3O(*"J[F[H(:J M5Y)(W?OO1O>=;^N5-^",VI=PT-6W%W64_J4TT@%G@!VPNQ2](3&^7253S#3A M;6&Y--4P/)EK2JA1MSI:BGH.7M0'/">BD#2_18E^[G9!2N+J$*@".TMI)+*> M00K] ;S0(UX:0_&8WY%N?L=;H](63$GJ"@:JUNYB&HE=22'5_@6\VN,TI&Q) M65'?(R\3C^B*%[,=T,\\HX9'>' E=Q@ MQ$%U0GU1C5Q@3*/Z.Y#;=#;Z04,+! TM$+PG"^A%?:,%@A<+0.[QV>CW&UJ@ MW] "_?=D ;VH;[1 _\4"D!M_)?HC_O&./=%UZC) %662_Q %7'QK0<=(?YA$ M"0^Y\U!!0$N/+F4H[:_54&I33\]J!D?D^S',7_D*6U?> "FE37@,"U=Y5U MC .T/,H'D+N'XIPU9!@9E#>%U!,AI1 \=1W4:_0LCU0*0NX(BN=DX_L%3NW_<)E,::Y(:8W(QM!@\,5WD:Y34AJHG92#WS6YIB;3A M(3<'0JZ*$0%/V/I":N0U)E B0^Z,J2/,]29D4')#[G@]TIB$).=> M_8IRS C2+\OL '6$-P#@J5Q;1MW1W3!>Z0NYSW7/L+ E3D-<_(-"_&6'WJ!<*!<0GNZ-RZK1WY5'^0!RGTOC/\ZR%6:-W6"%FSUA@(-W1EV)Q_G# MD$VYY-1>VJ5?6<()WR#^@+Z+B!?QA^V/_P-02P,$% @ V("I6([ I2JS M$@ K'P !$ !E9C(P,#(X-S@R7SAK+FAT;>U=:7/;.-+^/K\"JZEL["U3 MXGW(QY8C.UGM)+9+]M1.[9HBZ;LJW$CIU*)21Q M-;J!!]T-H'7PS]M1B+ZQ).5Q=/A>:ZOO$8M(3'ET??C^^++7[[__Y]$O!\,, MLD'6*.W>^DG(#UO#+!MW.YV;FYNV^-*.D^N.KJI&AT=IAB/"6D7^D$=?[\@N MDGV<5MEOE_+?&#*WYGE>1Z9665.^*B-4JW7^^/+YD@S9""N+](CFZ:Q@G1J[ MDR>667D:F[KFW-79/$=9($VR*G. 4U]FA(^063>J6F_75:@)[D$/V1\?!I]G MV;/5^6=9.UF"HS2(DQ'.0(ZB-551=473:Y4H*2-S%<%[^SK^=F<]FJ6HKF)H M93V35+G&>+S!)ER71UYB)QOL D26"8KBM1I,X3 MDR5*-AVS=#4S(;DCDD4975&->I^S9.T(\#J06F:,,"?I:I)DTAP]*2>KLT+" M?,9LG*S)"2ES6=DM&:[.*E+F.XRBE>?!Z'\35TITWBD,_211S"5.0[191Q.Q!A-]U _(FU95/XYB4C9#@#?B>9YF+" "-)(M_D^MTMR)<]7DE^D8])1I5OG(KW@+,$21K9R@6EU_]MOON+A8_*3_.U MCX$[,2W?8-5.LA.8PD>"*$6%E<@KR\W2*C+IFJQE2OE>-M*9XT/)M(I+G=J( M[\!T@2D+ 15C6]1&H><(C^$>5RE9_&XB\S%Q"$3>"4)N)T!03';[P"".10!O,U8LH]& M.+GFD2) I8OP)(NK3TG>BOPFH$QVJ.I:_ESV;E7-FX"<*4!.?K@I.N?'(07N M_G[6OSH]09=7QU>GES,6?[?V+T][OP_Z5_W32W1\=H)._^C]Z_CLTRGJG7_Y MTK^\[)^?;8\H?1U1_\'I$-:X+([VT$F[UX8URS*]94*.#ORD<[0] MUU!'X\ M'WQ!:[&X7+'S=;."X"!0,6&,JK9KF*9//,>V?--S-%T/F&;[#2#857Y;QMX- M>M^Z>[+?QYP:&-R-&5(NE0ZR!"!/+2=UG9Q@; ].SZ[0X/3B?'#UQJH[6'4Q M2=()!C4SB]$E(T(519J!X@1IU@[=17& LB$329.$9QR:. 45'$>@01Z33"1K MGF&^L;AL5*S1@BL#-HZ3#.V4[PS#*LW2#+%O0JE/9#*CN]W[\>1"KO2G^?I? M Q90ZES+#0R?N:KIJ:;K8TW#I@J@0A@EVH9:*(7:E1&4& H2%(JGRA2H5D"= M/OJ"I\C;DS;$&Q MB5Y?N\S>H[EUA>\.RZ],6D71O"+:6/W;=K=W3F]!H%+R @:22N((IR@=,R(,"8IXA'B6 M(D!60(5DMQE5N<6\W.;??]5L=?]A_]XQ)#+LAPQ8$88PG8APK+:$_0CO8TQI M^9[+03X^U"MPPVDV%"_JN\ID@"$0XG$*>W\5B8C="9 M%T4\'F3)4>U+D7R0T;)_!;F& =1^8TG&"0Y+LL#26='!!3-)KRRA.<);\\T^ M>G3>"T?]B,0)K$O2:7J9P7K0RWV6O9C6T8G9JJ9KFDL]4S-UU?$"RP!44JFK M8L>EQF8+C_#G"D,X8^,D_B9H$BO."0OQ#4Z6/2%SR#XW3N<_9;29U,R7+K6/ M/&20YK.D+B)3P[ZA.PXFCFF Z4$"3R>V[H-\,+&=1GX?33%L1W>W+H(7/W&N M\&V_< H1.7F6Y.%KJDVQ;6I,"TS#A[5-MWS'#QRJNBXS&TR9(\M6= O4/%-_ M(H'\(C\EBY^>'.Z>7AP[$IR$D1*#<9*@/\$V22G/K1=897D=R':_$SRL5'=W M>O%HQ%.Q*XG$1$7YR-C=QN1824"^JN_T!Y?H=#0.XRFP:WZLHK.XO43/TM@H M'GZ!KT(-N,]9]J::-%%-'JUSF-Y+A\YC2A.6IL5_GWG$M+KO3 TLS2"&1JAF M,M/V+>H8E.@^"W3J&7H#V#1M"^5P,8@G\*_F+,+GWGH3?([&'CR>)U?Q352C MT#$;=10PB#?_+QPLJOJ$:KHT]UPA)YX * MH^JJH;F^W41_=$S3?A:J2G-I;4%5*1@MU))Q C.4CW&(V"TCDXQ_$SX!6(=9 MNJ&2LJ7ILL5YL 7.PJA%8M@VX=V3Z#,_I_>R:'3FB_S[KZZN.?LIC)"0C8=Q MQ% DM=8]H5B'$Z%/(3#-,0Q#"A7LK(4:L6(>0\8%<#&=P-%T3$A@4M-SL4\= MR_.9KZNJRZC7X/C$D:YJB]"R.^/8.GH^QS!,+T2/E@PTL,V(J[F,F13^JMBW M+4)M3 DCC*D^;J)I.*YB6=:R>?92/>0O1ZLN/<./5JAS$A81+5^\'[&XKX;5 MQZUJFY&Z!?S]",HA6).Y:SN1NB*\XGR] ZP(4+Y1"(0+S12%."TWOMIOF+W2 M5MX(L7M#1K[*W5D\!IT+N*@IG("O4X9*[B+/K&():!-]2,@9I)[ M?X[;>COO_VYW _8_LV%2R](,A E,KC0_!_D91',E"CT-'K<6IN0B5I6-K-(" MET!G$N186*M__"?A&(!?&67(>!',>*D,%==!5;L.^58E\_324*\2 \YEIJ2Z8757 MKGLVL+\#Z]>["?/59JKIOIR]-7U0Z)L8:\2BQ0+H:\6V_ MR14)<>=Q^[=5[H>YUR'(KQV+Z[45;^*DL#UU7]$;QCJH M*A(0G;D:MIAI-0BQ\E#'T)N@U^!!<,<,%^>(5\(%7SI>-H3IST)&1 "\*);. MA4G*9"Z@LCC$)H(]+-JJ&S#;YO,EY.C%>OO](F+76 M,&C84ERP>M"PI8AB/RAHV)H(:HTF:\[N]5PG(<.)/,D[K-K/.Z_6G+=5C#7) MYG*SX\/@XN,%OF8?$H:_BJ/W=0'4VAA#'L47F10<9$(6.+S!TW1-37-:94V0 M.2VYS*0 5GFKBF_J3%B;QONH43 M:R5%3:X0WV'?-.K0 OTP-B9A)N]GGQ. /C7@K3V8EBO1,*6C(>[E^S' M*1D/@.SS"-4"/NVA/)10&2XW#U0+.GPZ@441P_HHKK1<$6; MD[&(6=5&QS"5QM4!]'EZ0"T/)DG$TR'4 :8(R[4!H=H/N<\SY'EMK?V/]3S> M2#:O 4_TMO,=$,5KBQM>+Q)1BI&5MK^7J^$GMB-$",*2GR]T]_45[A1JVI-? M"VXT@!;$+LM31HI ,-W\9('XD8#9+!713]8?&&B,0.[37X1^\AZ?L)0D?)SK M,4U[_+AMK!\X$##*HXVS0%=5W75<_7_LUO,4K3W,1JTCL>P?=/ +%?I*C>Q" M*CZ#7/'90U3^:L!>]FMV)VI=T=2N>@[ MW1-G+]A8ADAEM]*>$S>36298"9, VBXBIY(Y(BHVI!.P(W%!ST:[,9N/&M3, M5-^J4V\A7^[TDAGOV/G=S'E<[_ER?/Q(3)EP_L9V\:UUI*^_#TX?$D+F!0#]GY,TX\'TB;Q>]4CX^2[47Q.>R+/+:6.@7K%] M12< 7@1/Y,] B04D#X$AF@%L3:$GD!#G\9]]!K ;"("#BBJF2)D6&84+:Q)! M65DMGF3#.(%>T(8H=P?+GI/ 7Z'-;*V*YO)==-#-3(154_"D;I'-O>TH^G#M/O ::!O)KRG#@W9 ML'^=M(..*1ZARS;ZE,1I"M]?UFQYX.C9N&;K1R&R.$FYX2"!E%]5Q&44WDCK'TH_%1D6>VB5_D M>69;^$]5;G4XU^]DX1OWFFW-SH4]L]\#JOWTY:-^.O.@(WXD5_YH;C8*C_X? M4$L#!!0 ( -B J5A&0)>]#SL !-K P 5 968R,# R.##DY M+3$N:'1M[7UY<]M(LN?_&['?H5;3_9X= ;)Y'[YB*8FV.6-+&DGN>1TO-C:* M0%%$&P0X."2K8S_\9F85#E*@=9$B0):CVY9 $*C*ROSE49E9[Z;AS/GP/_\' M8^^F@EOT$_P&'?H>MWS;NA+LH^UR MU[2YPRX\)PIMSPT,-G+-JOPN_3GVS&@FW)"9ON A/",*;/C3WKEHVO M3,_Q_/<'?YO0GP,6A+>.>'\P\=RP,N$SV[E]P_[STIZ)@)V(&W;NS;C[GV\9 M?1[8?XDWK%Z;AV]9*'Z$%>[85^X;YH@)7*$GOV%_J]&?MP?R_?C%A9=D'W+/ M6P\^P/CQ'ODHR[Z.R3_UF>L%4V[!4]4/!XQ&\_X %B44?C*SJ4 RO6&M^8\[ M8V1C;GZ_\KW(M2K+'V4G*!_YELVX?V6[%9SO&\:CT$LN^?(E\MK8\RT!SW(] M5R@Z+ Q?_A(/,.]%CZ=4RANKGDU#A#OO+LF-(M'8,+\Q]_JG=K;U4]<2?['2$,>&0?'7P?LT :VNK+-@ U<%_C, MA"=]M/T@9/^,N \ODX*;0L:Y""(G#!AW+7;F>]>V!=\X1'000<"^S2U BW*2 MAQ[XAMDA/,V$-]?_*>=^Z84T[VOA1H)Y$_9+KU[MLZ^VXP!T&HRS5NM7Q$] MRD"P/RI>Y8_=HL"GP> ,OA[B)+V9I$&]6^UE:? +Z(%.?&&GJ3&P_HP"5(G# MP]'E\>!=$,WCEU\+/[1-[L0#H,&$WOPM&&O462;3$P_=_OYZ2 M=)>(V'X@$4-)A.9SJ=C9,2H>>>Y$^ +G? 0HQB[,J; B!R8^\7R08XO?,AZR MUIMFC.6KL9C1YUG]#Z" W+-N_/!UXOA M'P8[J?Z]2MQZ>'HT8.>#R],3@WW\8K"OL#9]@Z DGN(SG:$*6[0II5?)7IWP MP.+_?D.?OF:O_N-OO4:C]A9_HQ]!'0*SA%/!U"='WFS.W5OUX6M0?BX3X *% M7@7^ 2=I-A,^6:-CVYM/N3_CIHA(\^*'^%UF"0M^#Z4(P@"C"3?#R 1B91Y;P%5!QM%E$[*6_YVUEB>) MM>QGK.6YM)8M4.7CV%Z.R%ZNWLMBF\6$)S,M9RZ?P_U=J]7K]5: M;?2/^(>E5:YWWP;9E0LBTT0*F/!4&]1\@.L4N1-@7D,N"RT6L<4BB<$V0BH; M[$; 4_PY#Q!HO-;!/==^#=@X&S? MA-,JX+5@<'\ CW#L\):>$82 =%?A%$> K[.!):XY6A;I@LX\>!.;\H#=@F+A M5]QVTX5'3 R XO8$6!,DS59J@N8^]N#)8"M6Z%WP6^C-*F@VXO?_1 L&YX*/ M6#"6C%B$ FZC1N(S]LGW C JP?8Y _Z#-[NAP8ZFMIBPX0]A1CCBE RG$Q@- MD!4?.$+0M6?JYM3IB^^!B>-Z5F-!_1?,' @+ L0&%T?#D]'O\$&KUWB;K+@O M3,^W6(1D_(O6 ^@>S5%#W-@PX:Y"3RX2FP$IYC6_;D M-KY[[@4V#9!GY)N#<'!+X&+GH4.5_(8).P&H@'B34IK;L]%+.I7/@<["20+ M$ (X!;A$(/)X\+6Y\&&-9V1BAE/?BZZF7A02$7#=B;LE-9!J$Y)\IGB%CR60 M ='$#U, V 5L:!T58 M2F8YM"XG4^::6#F!,K#N11!ZKF0-=CK^4_J>P9O2S+,AB?7#RL3O5U>D-9'@ZU(L?NDE'ST/]R<^ MY$71

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ef20028782_8k_htm.xml IDEA: XBRL DOCUMENT 0001368514 2024-05-09 2024-05-09 false 0001368514 8-K 2024-05-09 ADMA BIOLOGICS, INC. DE 001-36728 56-2590442 465 State Route 17 Ramsey NJ 07446 201 478-5552 false false false false Common Stock ADMA NASDAQ false